 Burlingame, California--Newsfile Corp. - June 28, 2021 - Humanigen, Inc. NASDAQ: HGEN Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, today announced that Humanigen has been added to the Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution.The event represents the ongoing accomplishments of Humanigen during a transformational year in developing lenzilumab for the treatment of newly hospitalized patients with COVID-19, and its... 